Visfatin: A putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk - Results from the PIOSTAT study

Hormone and Metabolic Research

Volumn 39, Issue 10, 2007, Pages 764-768

  Pfutzner A ^a,b,c   Hanefeld, M ^d   Lubben G ^e   Weber, M M ^f   Karaglannis, E ^e   Kohler C ^d   Hohberg, C ^b   Forst, T ^b,f  

^a Institute for Clinical Research and Development   (Germany)

^b Institute for Clinical Research and Development   (Germany)

^c UNIVERSITY OF APPLIED SCIENCES   (Germany)

^d GWT   (Germany)

^e Takeda Pharma GmbH   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Adiponectin; Metabolic syndrome; Pioglitazone; Simvastatin; Visfatin

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; SIMVASTATIN; VISFATIN;

ADULT; AGED; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLACEBOS; RISK FACTORS; SIMVASTATIN; THIAZOLIDINEDIONES;

EID: 36049008208     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985867     Document Type: Conference Paper

References (24)

1. Rajala MW, Scherer PE. Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765-3773
2. Arner P. Insulin resistance in type 2 diabetes - role of adipokines. Curr Mol Med 2005; 5: 333-339
3. Schöndorf T, Maiworm A, Emission N, Forst T, Pfützner A. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab 2005; 51: 489-494
4. Thamer C, Haap M, Heller E, Joel L, Braun S, Tschritter O, Häring H, Fritsche A. Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors for the change of postprandial glucose in non-diabetic subjects at risk for type 2 diabetes. Horm Metab Res 2006; 38: 178-182
5. Heliövaara MK, Strandberg TE, Karonen SL, Ebeling P. Association of serum adiponectin concentrations to lipid and glucose metabolism in healthy humans. Horm Metab Res 2006; 38: 336-340
6. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-919
7. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
8. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that minimes the effects of insulin. Science 2005; 307: 426-430
9. Chen MP, Chung FM, Chang DM, Tsai JCR, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony enhancement factor in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 295-299
10. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91: 3165-3170
11. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914
12. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T. Anti-Inflammatory effect of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitive CRP: The PIOSTAT study. J Am Coll Cardiol 2007; 49: 290-297
13. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Köhler C, Baurecht W, Hohberg C, Hanefeld M. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism 2007; 56: 491-496
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
15. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 2000; 17: 299-307
16. Forst T, Hohberg C, Fuellert S, Lübben G, Konrad T, Löbig M, Weber MM, Sachara C, Gottschall V, Pfützner A. Pharmacological PPAR, stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 2005; 37: 521-527
17. Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T. Impact of rosiglitazone on β-cell function, insulin resistance and adiponektin concentrations - results from a double blind oral combination study with glimepiride. Metabolism 2006; 55: 20-25
18. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176
19. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, MacNulty JA, Winegar DA, Strum JC, Stimpson SA, Pahel GL. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004; 4: 23
20. Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, Smith U. Visfatin is an adipokine, but is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91: 1181-1184
21. Haider DG, Mittermayer F, Schaller G, Artwohl M, Baumgartner-Parzer SM, Prager G, Roden M, Wolzt M. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab 2006; 291: E885-E890
22. Goldberg RB, Kendall DM, Deeg MA Buse JB, Zagar AJ, Pinaire JA Tan MH, Khan MA, Perez AT, Jacober SJ, GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554
23. Pfützner A, Marx N, Walcher D, Löbig M, Seidel DD, Forst T. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease. Clin Lab in press
24. Pfützner A, Forst T, Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin (Diabetologia 2006; 49: 1909-1914). Diabetologia 2006; 49: 2795